High Rate of Second Neoplasms in Patients with a Bronchial Neuroendocrine Tumor Abstract #1745

Introduction: Bronchial neuroendocrine tumors (NETs) are classified as typical carcinoids (TC), atypical carcinoids (AC), large cell neuroendocrine carcinomas (LCNEC), or small cell lung carcinomas (SCLC)
Aim(s): We retrospectively reviewed the management, long-term follow-up and clinical outcome of bronchial NETs at our institution
Materials and methods: All patients diagnosed with TC, AC, or LCNEC at our institution from 1995 to 2015 have been included. Patients with SCLC were excluded. Clinical, diagnostic, therapeutic and follow-up data have been collected and analyzed
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Federica Alessandra Cavalcoli

To read results and conclusion, please login ...

Further abstracts you may be interested in

#173 Temozolomide in Metastatic Bronchial Carcinoids
Introduction: Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment thus far have been disappointing. Temozolomide has, however, shown some activity in a small prior study.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel P Lindholm
#2166 A Family Bronchial Carcinoid Tumor.
Introduction: Typical and atypical bronchial carcinoids are neuroendocrine tumors of the lung. Family lung carcinoid tumors are rare and have been described as very rarely in literature.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Pr Bezzar-Ghomari Soumeyya
#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study
Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. Nicola Fazio
#749 Natural History of Atypical Carcinoid of Lung After Surgery
Introduction: The natural history of atypical carcinoid (AC) is poorly known.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Francesca Marciello
#1938 Eleven Years Survival after Combined Treatment of Surgery, Ultrasound-Guided Radiofrequency Ablation of Liver Metastasis, CT Embolization Plus Somatostatin LAR in a Case with Atypical Carcinoid of the Lung
Introduction: The combination of different therapeutic methods has an important place in the treatment of patients with NET and liver metastasis, ineligible for radical surgery.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Borislav Vladimirov